Northern Trust Corp Has $13.87 Million Stock Holdings in RxSight, Inc. (NASDAQ:RXST)

Northern Trust Corp boosted its position in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 6.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 403,404 shares of the company's stock after acquiring an additional 26,106 shares during the quarter. Northern Trust Corp owned about 1.00% of RxSight worth $13,869,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. DF Dent & Co. Inc. acquired a new position in shares of RxSight in the 4th quarter valued at about $14,524,000. Artisan Partners Limited Partnership lifted its holdings in RxSight by 32.6% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,551,620 shares of the company's stock valued at $53,345,000 after acquiring an additional 381,389 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in RxSight by 196.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 359,144 shares of the company's stock valued at $12,346,000 after acquiring an additional 237,877 shares during the last quarter. Renaissance Technologies LLC lifted its stake in RxSight by 102.9% during the fourth quarter. Renaissance Technologies LLC now owns 361,500 shares of the company's stock worth $12,428,000 after purchasing an additional 183,300 shares in the last quarter. Finally, Altium Capital Management LLC lifted its stake in RxSight by 154.5% during the fourth quarter. Altium Capital Management LLC now owns 285,000 shares of the company's stock worth $9,798,000 after purchasing an additional 173,000 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company's stock.

RxSight Stock Up 15.0%

NASDAQ:RXST traded up $2.13 during trading hours on Monday, reaching $16.32. 1,808,804 shares of the company's stock were exchanged, compared to its average volume of 678,517. The company has a market capitalization of $663.20 million, a P/E ratio of -19.66 and a beta of 1.32. RxSight, Inc. has a 12 month low of $12.53 and a 12 month high of $64.50. The business's 50-day simple moving average is $18.08 and its two-hundred day simple moving average is $29.96.

RxSight (NASDAQ:RXST - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.03) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.03). The firm had revenue of $37.90 million during the quarter, compared to analysts' expectations of $38.74 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The firm's revenue for the quarter was up 28.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.25) earnings per share. As a group, sell-side analysts anticipate that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on RXST. UBS Group cut RxSight from a "buy" rating to a "neutral" rating and cut their target price for the stock from $45.00 to $16.00 in a research report on Wednesday, April 9th. JPMorgan Chase & Co. reiterated an "underweight" rating and set a $17.00 target price (down previously from $40.00) on shares of RxSight in a research report on Friday, April 4th. Piper Sandler began coverage on RxSight in a research report on Tuesday, April 15th. They set a "neutral" rating and a $18.00 target price on the stock. Needham & Company LLC reissued a "buy" rating and set a $43.00 price target on shares of RxSight in a report on Thursday, April 3rd. Finally, Bank of America reaffirmed an "underperform" rating and issued a $22.00 price objective (down previously from $36.00) on shares of RxSight in a report on Thursday, April 3rd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $37.90.

Insider Buying and Selling

In other news, Director Tamara Fountain sold 7,000 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total transaction of $179,970.00. Following the transaction, the director now owns 24,793 shares in the company, valued at approximately $637,428.03. This trade represents a 22.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 9.36% of the company's stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.